A phase Ib study of pertuzumab, a recombinant humanised antibody to HER2, and docetaxel in patients with advanced solid tumours

Pertuzumab represents the first in a new class of targeted therapeutics known as HER dimerisation inhibitors. We conducted a phase Ib study to determine the maximum-tolerated dose, the dose limiting toxicities (DLT), and pharmacokinetic (PK) interaction of docetaxel when administered in combination...

Descripción completa

Detalles Bibliográficos
Autores principales: Attard, G, Kitzen, J, Blagden, S P, Fong, P C, Pronk, L C, Zhi, J, Zugmaier, G, Verweij, J, de Bono, J S, de Jonge, M
Formato: Texto
Lenguaje:English
Publicado: Nature Publishing Group 2007
Materias:
Clinical Study
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360237/
https://www.ncbi.nlm.nih.gov/pubmed/18000498
http://dx.doi.org/10.1038/sj.bjc.6604043

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2360237/
https://www.ncbi.nlm.nih.gov/pubmed/18000498
http://dx.doi.org/10.1038/sj.bjc.6604043

Ejemplares similares